Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients Horn, L., Wu, Y., Reck, M., Wakelee, H. A., Liang, C., Tan, F., Harrow, K., Oertel, V., Dukart, G., Mok, T. AMER SOC CLINICAL ONCOLOGY. 2018
View details for DOI 10.1200/JCO.2018.36.15_suppl.TPS9115
View details for Web of Science ID 000442916008019